Literature DB >> 8168080

Cellular interactions of CRKL, and SH2-SH3 adaptor protein.

J ten Hoeve1, V Kaartinen, T Fioretos, L Haataja, J W Voncken, N Heisterkamp, J Groffen.   

Abstract

Chronic myelogenous leukemia is characterized by a specific chromosomal translocation, t(9;22), in which the ABL protooncogene and the BCR gene become juxtaposed. The chimeric BCR/ABL gene produces a P210 fusion protein with deregulated tyrosine kinase activity. We have recently isolated a complementary DNA, CRKL, which could code for an adaptor protein consisting of one SH2 and two SH3 domains and lacking any catalytic domain. In the current study, we show that CRKL is highly phosphorylated in the chronic myelogenous leukemia cell line K562 and that it is a substrate for the p210 BCR/ABL and p145 ABL kinases. BCR/ABL and ABL are coimmunoprecipitated with CRKL in vivo, demonstrating that relatively stable complexes are formed. In addition, the nucleotide exchange factor mSOS1 was found to be coimmunoprecipitated with CRKL. These findings establish a putative signal transduction pathway way through which BCR/ABL mediates its oncogenic activity.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8168080

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  27 in total

1.  Downstream of tyrosine kinase 1 and 2 play opposing roles in CD200 receptor signaling.

Authors:  Robin Mihrshahi; Marion H Brown
Journal:  J Immunol       Date:  2010-11-15       Impact factor: 5.422

2.  Interaction of hematopoietic progenitor kinase 1 with adapter proteins Crk and CrkL leads to synergistic activation of c-Jun N-terminal kinase.

Authors:  P Ling; Z Yao; C F Meyer; X S Wang; W Oehrl; S M Feller; T H Tan
Journal:  Mol Cell Biol       Date:  1999-02       Impact factor: 4.272

3.  Insulin regulates the dynamic balance between Ras and Rap1 signaling by coordinating the assembly states of the Grb2-SOS and CrkII-C3G complexes.

Authors:  S Okada; M Matsuda; M Anafi; T Pawson; J E Pessin
Journal:  EMBO J       Date:  1998-05-01       Impact factor: 11.598

4.  CRKL protein overexpression enhances cell proliferation and invasion in pancreatic cancer.

Authors:  Lin Fu; Qianze Dong; Chengyao Xie; Yan Wang; Qingchang Li
Journal:  Tumour Biol       Date:  2014-10-16

5.  Expression level of CRKL and AXL combined with exon 19 deletion in EGFR and ALK status confer differential prognosis of lung adenocarcinoma subtypes.

Authors:  Yi-Ran Cai; Yu-Jie Dong; Hong-Bo Wu; Da-Ping Yu; Li-Juan Zhou; Dan Su; Li Zhang; Xue-Jing Chen
Journal:  Oncol Lett       Date:  2016-09-02       Impact factor: 2.967

6.  Structural requirements for function of the Crkl adapter protein in fibroblasts and hematopoietic cells.

Authors:  K Senechal; C Heaney; B Druker; C L Sawyers
Journal:  Mol Cell Biol       Date:  1998-09       Impact factor: 4.272

7.  Murine model indicates 22q11.2 signaling adaptor CRKL is a dosage-sensitive regulator of genitourinary development.

Authors:  Meade Haller; Qianxing Mo; Akira Imamoto; Dolores J Lamb
Journal:  Proc Natl Acad Sci U S A       Date:  2017-04-24       Impact factor: 11.205

Review 8.  Recent advances in the understanding of interleukin-2 signal transduction.

Authors:  F Gesbert; M Delespine-Carmagnat; J Bertoglio
Journal:  J Clin Immunol       Date:  1998-09       Impact factor: 8.317

9.  The RhoGEF domain of p210 Bcr-Abl activates RhoA and is required for transformation.

Authors:  S Sahay; N L Pannucci; G M Mahon; P L Rodriguez; N J Megjugorac; E V Kostenko; H L Ozer; I P Whitehead
Journal:  Oncogene       Date:  2007-10-08       Impact factor: 9.867

10.  Overexpression of CRKL correlates with malignant cell proliferation in breast cancer.

Authors:  Tingting Zhao; Zhifeng Miao; Zhenning Wang; Yingying Xu; Jianhua Wu; Xingyu Liu; Yi You; Jiguang Li
Journal:  Tumour Biol       Date:  2013-05-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.